Login / Signup

Successful use of transarterial radioembolization with yttrium-90 (TARE-Y90) in two children with hepatoblastoma.

Allison AguadoStephen P DunnLauren W AverillKudakwashe R ChikwavaRenee GreshDeborah RabinowitzHoward M Katzenstein
Published in: Pediatric blood & cancer (2020)
Primary malignant liver tumors are rare but all require surgical resection as part of therapy with curative intent. A minority of patients have resectable tumors at diagnosis. Chemotherapy has a therapeutic role in hepatoblastoma but only one-third of patients have resectable disease at diagnosis. Two children with hepatoblastoma and suboptimal responses to initial chemotherapy received therapy with transarterial radioembolization utilizing yttrium-90 (TARE-Y90) and had significant response leading to resection and remission. The role of TARE-Y90 needs to be studied further to define its use in primary pediatric liver neoplasms.
Keyphrases
  • end stage renal disease
  • liver metastases
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • locally advanced
  • peritoneal dialysis
  • squamous cell carcinoma
  • systemic lupus erythematosus
  • replacement therapy